Abstract 2303P
Background
The interpretation of gene variants from NGS data may support clinical and treatment decisions in pleural mesothelioma. Predicting how a variant can affect the functions of the protein- or disease-relevant pathways is challenging and, so far, it largely relies on gene-centric algorithms. We complement this by integrating a protein-centric interpretation of the variants in order to expand the functional information accessible from clinical NGS.
Methods
We have screened for pleural mesothelioma clinical NGS datasets accessible from literature reports focusing on the relevant genes BAP1 and NF2. NGS results are combined with protein information from neXtProt using an in-house developed program. Conservation-based predictions are integrated with structural and functional protein information to assess the functional impact of the variants. The pleural mesothelioma molecular pathway in the WikiPathways knowledgebase permits us to interpret the relevance of the variant within its pathway environment (https://www.wikipathways.org/pathways/WP5087.html).
Results
The variants from an initial NGS dataset have been mapped on the protein sequences, resulting in 209 protein variants for BAP1 and 181 for NF2 isoform 1. Functional predictions from the algorithms SIFT and PolyPhen-2 embedded in neXtProt presented approx. 60% agreement for BAP1 and 51% for NF2. 13% of the BAP1 and 22% of the NF2 variants had no prediction. The integration of the protein-centric information refined the functional interpretation of 121 variants in BAP1 and 107 in NF2 located in regions critical for the function of the proteins, like interacting or enzymatically active domains, FERM domains or loci of post-translational modifications. Among them, 67 variants with missing or ambiguous prediction between SIFT and PolyPhen-2 (30 in BAP1, 37 in NF2). The molecular pathways of pleural mesothelioma revealed critical sites in the BAP1 and NF2 pathways potentially affected by the variants (WikiPathways:WP5087; Malignant pleural mesothelioma (WP5087)).
Conclusions
Protein-centric and pathway-embedded interpretation of gene variants may complement NGS information for clinical decisions in pleural mesothelioma.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
The Marlies Schwegler Foundation.
Disclosure
F.W.F. Cerciello: Financial Interests, Institutional, Advisory Board: Bristol Myers Squibb, PharmaMar. All other authors have declared no conflicts of interest.
Resources from the same session
2262P - Baseline-informed versus tumor-agnostic minimal residual disease (MRD) concordance study in patients with HER2+ gastroesophageal adenocarcinoma patients
Presenter: Pan Du
Session: Poster session 08
2263P - Ethnicity-specific distribution of BRCA1, BRCA2, PALB2 and ATM pathogenic alleles in breast and ovarian cancer patients from the North Caucasus
Presenter: Evgeny Imyanitov
Session: Poster session 08
2264P - Proteomics-based phenotypic classification of non-smallcell lung cancer
Presenter: Olena Berkovska
Session: Poster session 08
2265P - miR-4487 enhances gefitinib-mediated ubiquitination and autophagic degradation of EGFR in non-small cell lung cancer cells by targeting USP37
Presenter: Sei-Hoon Yang
Session: Poster session 08
2266P - IMMUcan consortium: Focus on the first results of the non-small cell lung cancer (NSCLC) cohort
Presenter: Marie Morfouace
Session: Poster session 08
2267P - Coronary heart disease and risk of lung cancer: A two-sample Mendelian randomization study
Presenter: Cai Chen Li
Session: Poster session 08
2269P - Patient derived xenografts generated from circulating cancer stem cells on chorioallantoic membrane as an alternative pre-clinical model for personalized medicine in pancreatic cancer
Presenter: Monika Pizon
Session: Poster session 08
2270P - Integrative analyses of bulk and single-cell RNA-seq identified diabetes mellitus-related signature as a prognostic factor in pancreatic adenocarcinoma
Presenter: Le Tang
Session: Poster session 08
2271P - Development of an oncolytic virus for the treatment of high grade serous ovarian cancer and other stromal rich tumours
Presenter: Miriam Bazan Peregrino
Session: Poster session 08
2272P - Minimal DNA-methylation (DNAm) signatures for non-invasive tumor-agnostic estimation of tumor content (TC) and molecular subtype in patients (pts) with metastatic breast cancer (mBC)
Presenter: Matteo Benelli
Session: Poster session 08